IS6678A - Hvarfefni og prófanir fyrir ß-sekretasavirkni - Google Patents

Hvarfefni og prófanir fyrir ß-sekretasavirkni

Info

Publication number
IS6678A
IS6678A IS6678A IS6678A IS6678A IS 6678 A IS6678 A IS 6678A IS 6678 A IS6678 A IS 6678A IS 6678 A IS6678 A IS 6678A IS 6678 A IS6678 A IS 6678A
Authority
IS
Iceland
Prior art keywords
reagents
tests
secretory activity
substrates
asp
Prior art date
Application number
IS6678A
Other languages
English (en)
Inventor
Yan Riqian
G. Tomasselli Alfredo
E. Gurney Mark
L. Emmons Thomas
Jerome Bienkowski Michael
L. Heinrikson Robert
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of IS6678A publication Critical patent/IS6678A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS6678A 2000-07-19 2003-01-14 Hvarfefni og prófanir fyrir ß-sekretasavirkni IS6678A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21979500P 2000-07-19 2000-07-19
US27525101P 2001-03-12 2001-03-12
PCT/US2001/023035 WO2002006306A2 (en) 2000-07-19 2001-07-19 SUBSTRATES AND ASSAYS FOR β-SECRETASE ACTIVITY

Publications (1)

Publication Number Publication Date
IS6678A true IS6678A (is) 2003-01-14

Family

ID=26914256

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6678A IS6678A (is) 2000-07-19 2003-01-14 Hvarfefni og prófanir fyrir ß-sekretasavirkni

Country Status (11)

Country Link
US (8) US7205120B2 (is)
EP (1) EP1301604B1 (is)
JP (1) JP2004504018A (is)
AT (1) ATE397077T1 (is)
AU (1) AU2001277950A1 (is)
CA (1) CA2410898A1 (is)
DE (1) DE60134230D1 (is)
IL (1) IL153943A0 (is)
IS (1) IS6678A (is)
TW (2) TW200628612A (is)
WO (1) WO2002006306A2 (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2350205A (en) 1998-04-06 2000-11-22 Imation Corp Reverse optical mastering for data storage disks
US7196163B2 (en) 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
TWI243826B (en) * 2001-07-19 2005-11-21 Akzo Nobel Nv Process for the preparation of peptides
IL150601A (en) * 2001-07-19 2010-06-30 Organon Nv Process for rapid synthesis of peptides within a solution using the back of an activated carboxyl component and destruction of the residual activated carboxyl component
AU2002253468B2 (en) * 2002-04-18 2008-04-03 Esbatech Ag Method for the identification of modulators of a secretase activity
JP2004000060A (ja) * 2002-05-31 2004-01-08 Otsuka Pharmaceut Co Ltd アミロイドβ産生に影響を与える化合物のスクリーニング方法
CA2505907A1 (en) * 2002-11-14 2004-06-03 Qtl Biosystems, Llc Methods of biosensing using fluorescent polymers and quencher-tether-ligand bioconjugates
US20050112696A1 (en) * 2003-11-25 2005-05-26 The University Of Texas Southwestern Medical Center Compositions, methods and assays related to secretase cleavage specificity
US20060098887A1 (en) * 2004-05-19 2006-05-11 Hazem El-Bakry Mehthod for image conversion
NZ561029A (en) * 2005-03-14 2011-03-31 High Point Pharmaceuticals Llc Benzazole dervatives, compositions, and method of use as beta-secretase inhibitors
DE102005051978A1 (de) * 2005-10-31 2007-05-10 Forschungszentrum Borstel Zentrum für Medizin und Biowissenschaften Verfahren zur Bestimmung der Spaltbarkeit von Substraten
JP4848986B2 (ja) * 2007-03-22 2011-12-28 富士ゼロックス株式会社 光導波路及びその製造方法
US8548257B2 (en) * 2009-01-05 2013-10-01 Apple Inc. Distinguishing between faces and non-faces
MX346500B (es) 2010-11-10 2017-03-22 Genentech Inc * Metodos y composiciones para inmunoterapia para enfermedad neural.
JP2013158281A (ja) * 2012-02-03 2013-08-19 Shionogi & Co Ltd 新規ｂａｃｅ１活性測定方法
WO2016081639A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292652A (en) 1990-10-05 1994-03-08 Athena Neurosciences, Inc. Amyloidin protease and uses thereof
US5798224A (en) * 1992-12-29 1998-08-25 Doheny Eye Institute Nucleic acids encoding protocadherin
JP4052605B2 (ja) * 1994-05-18 2008-02-27 タカラバイオ株式会社 α−１，３／４−フコシダーゼ遺伝子
US5942400A (en) * 1995-06-07 1999-08-24 Elan Pharmaceuticals, Inc. Assays for detecting β-secretase
US6803188B1 (en) * 1996-01-31 2004-10-12 The Regents Of The University Of California Tandem fluorescent protein constructs
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
WO1999040930A1 (en) * 1998-02-12 1999-08-19 Center For Blood Research, Inc. Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases
US7090976B2 (en) * 1999-11-10 2006-08-15 Rigel Pharmaceuticals, Inc. Methods and compositions comprising Renilla GFP
IL139739A0 (en) * 1998-06-05 2002-02-10 Aventis Pharma Sa Polypeptides with beta-secretase type activity
EP1100520B1 (en) * 1998-07-21 2004-09-22 Cytovia, Inc. Novel fluorescence dyes and their applications for whole cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof
CN1300320C (zh) 1998-09-24 2007-02-14 法玛西雅厄普约翰美国公司 阿尔茨海默氏疾病分泌酶
US6313268B1 (en) * 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
CN1390232A (zh) 1999-02-10 2003-01-08 艾兰制药公司 人β分泌酶、抑制剂、其组合物和用途
AU3770800A (en) 1999-03-26 2000-10-16 Amgen, Inc. Beta secretase genes and polypeptides
JP4484410B2 (ja) * 1999-06-28 2010-06-16 オクラホマ メディカル リサーチ ファウンデーション メマプシン２のインヒビターおよびその使用
US7429639B2 (en) * 1999-09-29 2008-09-30 Ludwig Institute For Cancer Research SSX-2 peptides presented by HLA class II molecules
GB9925136D0 (en) * 1999-10-22 1999-12-22 Smithkline Beecham Plc Novel treatment
DE60031792T2 (de) * 1999-12-08 2007-02-22 Intellect Neurosciences, Inc. Schimärische amyloid-beta peptide
JP2003528071A (ja) * 2000-03-23 2003-09-24 エラン ファーマスーティカルズ インコーポレイテッド アルツハイマー病治療用組成物および方法
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
WO2002094985A2 (en) 2001-05-22 2002-11-28 Merck & Co., Inc. Beta-secretase substrates and uses thereof

Also Published As

Publication number Publication date
US7888291B2 (en) 2011-02-15
US20040254341A1 (en) 2004-12-16
DE60134230D1 (de) 2008-07-10
CA2410898A1 (en) 2002-01-24
EP1301604B1 (en) 2008-05-28
US20040253706A1 (en) 2004-12-16
ATE397077T1 (de) 2008-06-15
WO2002006306A2 (en) 2002-01-24
US20030017991A1 (en) 2003-01-23
TW200628612A (en) 2006-08-16
EP1301604A2 (en) 2003-04-16
AU2001277950A1 (en) 2002-01-30
US20040254342A1 (en) 2004-12-16
WO2002006306A3 (en) 2002-07-25
US20080299596A1 (en) 2008-12-04
US7205120B2 (en) 2007-04-17
US20080090260A1 (en) 2008-04-17
US20050096457A1 (en) 2005-05-05
US20040241792A1 (en) 2004-12-02
IL153943A0 (en) 2003-07-31
US7803739B2 (en) 2010-09-28
JP2004504018A (ja) 2004-02-12
TWI316960B (en) 2009-11-11

Similar Documents

Publication Publication Date Title
IS6678A (is) Hvarfefni og prófanir fyrir ß-sekretasavirkni
ATE500323T1 (de) Subtilisin-variante
ATE380822T1 (de) Funf-helix protein
MXPA04003333A (es) Remodelado y glicoconjugacion de peptidos.
DK1229047T3 (da) IL-1-receptor-fusionsproteiner anvendt som antagonister og fremgangsmåder til fremstilling og anvendelse
IL150168A0 (en) Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods bsed thereon
DK1259547T3 (da) Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
DK1149905T3 (da) Fremgangsmåder og præparat til polypeptidteknologi
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
NO20043419L (no) Nytt cytokin, zcytor17-ligand
DK1084146T3 (da) Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf
BR9813608B1 (pt) célula hospedeira de bacillus transgênica, e, processo para produzir um polipeptìdeo tendo atividade aminopeptidase.
ATE350470T1 (de) Durch thrombin spaltbare chimäre proteine
ATE382148T1 (de) Antikörper für apoptosemarker und anwendungsverfahren
DE602005026855D1 (de) Vorrichtungen und verfahren zur bestimmung von proteaseaktivität
DK372086D0 (da) Fremgangsmaade til rekombinant-dna-syntese af en serinproteaseinhibitor og dna-sekvenser, som er nyttige derved
NO20052552D0 (no) Loselige Notch-baserte substrater for gamma-sekretase og fremgangsmater og blandinger for anvendelse av samme.
DE60118935D1 (de) Dna & protein bindende miniatur proteine
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
DE69938130D1 (de) Neue peptide
DK0994187T3 (da) Renin-aktivt stof omfattende humant prorenin og antistoffer mod prorenin-profragmentet
SE0101519D0 (sv) Nucleic ACID
DE50109166D1 (de) Verfahren zur verbesserung der transfektionseffizienz
DK1534741T3 (da) Fiberformende peptider i stand til at interagere med selvsamlende peptider